Clinical Trial

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Study acronym: RIVERS
Recruiting
View on ClinicalTrials.gov →
Summary
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Protocol Amendment History 1 change
notable Trial sites expanded: 19 -> 22 locations 2026-05-29
Trial Details
NCT Number NCT07038928
Lead Sponsor AstraZeneca
Conditions Bladder Cancer
Enrollment 600 participants
Start Date 2025-06-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10